A preliminary study found that adults with type 2 diabetes and a moderate or high risk of cardiovascular disease were less likely to experience a serious cardiovascular event when taking low-dose ...

BERLIN, Nov 23 (Reuters) - German pharma company Bayer (BAYGn.DE), opens new tab reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bayer reported positive results in a late-stage trial of an experimental stroke prevention medicine, sending ...

Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Puhe BioPharma and Youngen Technology.

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals, a development that also helped a rival creating a competing drug. Bayer didn’t ...

If you have ever wondered whether Bayer is really a bargain or just another risky pharma play, you are not alone. Let's dig into whether its current price matches up to its true worth. After a sharp ...

This article first appeared on GuruFocus. Bayer AG (BAYRY) just picked up a shot of momentum from the US Food and Drug Administration, which granted accelerated approval for Hyrnuo, its new treatment ...

Below, Pasquariello breaks down some of the benefits you can realistically expect from a supplement like Daily Dose, her ...

SAO PAULO, Nov 26 (Reuters) - German conglomerate Bayer (BAYGn.DE), opens new tab on Wednesday said it will sell a new soybean product called Intacta 5+ for farmers in Brazil, the world's largest ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor type in patients with non-small cell lung cancer (NSCLC), the FDA has given ...

A Bayer drug designed to target tumors driven by a rare genetic mutation now has accelerated FDA approval, providing another treatment option for certain patients with advanced cases of lung cancer.